Literature DB >> 3400274

Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences.

W Krause1, G Kühne.   

Abstract

1. The pharmacokinetics of rolipram were studied in rat, rabbit, rhesus monkey and cynomolgus monkey using 14C- or 3H-labelled rolipram and a radioimmunoassay for measurement of unchanged drug. 2. Rolipram was rapidly and completely absorbed after oral doses of up to 50 mg/kg. Bioavailability was 0.1% in rhesus monkey, 3.7% in cynomolgus monkey, 3.6% in rabbit, 35% in rat, and 75% in man. 3. Rolipram was able to pass the blood-brain barrier achieving concentrations in brain twice those in plasma. 4. Plasma levels of the unchanged drug declined with a similar half-life of 1-3 h in all species investigated. In the rat, there were indications for a different clearance of the two rolipram enantiomers. 5. Labelled rolipram was excreted rapidly and completely. The main route of elimination was via the urine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3400274     DOI: 10.3109/00498258809041693

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  38 in total

1.  SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.

Authors:  K W Ward; J W Proksch; L M Azzarano; K L Salyers; J E McSurdy-Freed; T M Molnar; M A Levy; B R Smith
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Investigations on the percutaneous absorption of the antidepressant rolipram in vitro and in vivo.

Authors:  J Hadgraft; S Hill; M Hümpel; L R Johnston; L R Lever; R Marks; T M Murphy; C Rapier
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

3.  Analysis of (R)- and (S)-[(11)C]rolipram kinetics in canine myocardium for the evaluation of phosphodiesterase-4 with PET.

Authors:  Mireille Lortie; Jean N DaSilva; Miran Kenk; Stephanie Thorn; Darryl Davis; David Birnie; Rob S B Beanlands; Robert A deKemp
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 4.  The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury.

Authors:  Sari S Hannila; Marie T Filbin
Journal:  Exp Neurol       Date:  2007-08-27       Impact factor: 5.330

5.  Activation of Hippocampal CREB by Rolipram Partially Recovers Balance Between TNF-α and IL-10 Levels and Improves Cognitive Deficits in Diabetic Rats.

Authors:  Ya Miao; Ting He; Yitong Zhu; Wei Li; Beiyuan Wang; Yuan Zhong
Journal:  Cell Mol Neurobiol       Date:  2015-05-23       Impact factor: 5.046

6.  Reduction of alcohol drinking of alcohol-preferring (P) and high-alcohol drinking (HAD1) rats by targeting phosphodiesterase-4 (PDE4).

Authors:  Kelle M Franklin; Sheketha R Hauser; Amy W Lasek; Jeanette McClintick; Zheng-Ming Ding; William J McBride; Richard L Bell
Journal:  Psychopharmacology (Berl)       Date:  2015-01-15       Impact factor: 4.530

7.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.

Authors:  Bing Gong; Ottavio V Vitolo; Fabrizio Trinchese; Shumin Liu; Michael Shelanski; Ottavio Arancio
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

8.  Rolipram Attenuates Early Brain Injury Following Experimental Subarachnoid Hemorrhage in Rats: Possibly via Regulating the SIRT1/NF-κB Pathway.

Authors:  Yucong Peng; Jianxiang Jin; Linfeng Fan; Hangzhe Xu; Pingyou He; Jianru Li; Ting Chen; Wu Ruan; Gao Chen
Journal:  Neurochem Res       Date:  2018-02-03       Impact factor: 3.996

9.  Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling.

Authors:  Eva Bollen; Daniela Puzzo; Kris Rutten; Lucia Privitera; Jochen De Vry; Tim Vanmierlo; Gunter Kenis; Agostino Palmeri; Rudi D'Hooge; Detlef Balschun; Harry M W Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Neuropsychopharmacology       Date:  2014-05-12       Impact factor: 7.853

10.  Development and assessment of countermeasure formulations for treatment of lung injury induced by chlorine inhalation.

Authors:  Gary W Hoyle; Jing Chen; Connie F Schlueter; Yiqun Mo; David M Humphrey; Greg Rawson; Joe A Niño; Kenneth H Carson
Journal:  Toxicol Appl Pharmacol       Date:  2016-03-04       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.